

**PRESCRIPTION ANIMAL REMEDY  
KEEP OUT OF REACH OF CHILDREN  
FOR ANIMAL TREATMENT ONLY**

# Metacam®

## Anti-inflammatory injectable for dogs and cats



### Composition

Clear yellow solution for injection containing 5 mg meloxicam per mL (and 150 mg of ethanol as preservative).

### Action

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, anti-exudative, analgesic and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue.

### Indications

Dogs - alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs.

Cats - reduction of pain after surgery. Management of febrile conditions in combination with appropriate antibiotics.

### DIRECTIONS FOR USE

**Discard unused product 28 days after first broaching vial.**

**DO NOT USE in pregnant or lactating animals as no data has been established.**

**DO NOT USE in animals suffering from gastrointestinal disorders such**

**as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders, or where there is evidence of individual hypersensitivity to the product.**

**As for all NSAIDs use in any animal less than 6 weeks of age or in debilitated aged animals may involve additional risk. If use in such animals cannot be avoided careful clinical management may be required.**

### Precautions

Cats: Metacam® should be used as a single dose of 0.3 mg meloxicam/kg. Safety trials have demonstrated that Metacam®, when administered subcutaneously at 0.3 mg/kg at 24 hour intervals for 3 consecutive days in cats, resulted in no side effects in trial animals.

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam® must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.

Pretreatment with other anti-inflammatory drugs prior to the use of Metacam® may result in additional or increased adverse effects and accord-

ingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement with Metacam® injection.

The treatment-free period, however, should take into account the pharmacokinetic properties of the drugs previously used.

Parenteral administration of Metacam® injection is well tolerated without local adverse reactions. Typical adverse reactions of NSAIDs include loss of appetite, vomiting, diarrhoea, faecal occult blood and apathy. These side effects are in most cases transient and disappear following termination of treatment but in rare cases may be serious.

Hypovolaemic or hypotension should be corrected prior to use of the product.

In case of overdosing a symptomatic treatment should be initiated.

Dogs:

Musculoskeletal disorders:

Single subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (ie. 0.4 mL/10 kg bodyweight). Metacam® Anti-Inflammatory Oral Suspension should be used for continuation of treatment at a dosage of 0.1 mg meloxicam/kg bodyweight, 24 hours after administration of the injection.

Reduction of post-operative pain:

Single intravenous or subcutaneous injection at a dosage of 0.2 mg meloxicam/kg bodyweight (ie. 0.4 mL/10 kg bodyweight) before surgery, for example at the time of induction of anaesthesia.

Cats:

Reduction of post-operative pain:

Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (ie. 0.06 mL/kg bodyweight)

directly prior to induction of anaesthesia.

Management of febrile conditions:  
Single subcutaneous injection at a dosage of 0.3 mg meloxicam/kg bodyweight (ie. 0.06 mL/kg bodyweight).

**First Aid**

If poisoning occurs, contact a doctor or Poisons Information Centre.

*Phone Australia 131126;  
New Zealand 0800 764 766  
(0800 POISON)*

**Disposal**

Dispose of empty container by wrapping with paper and putting in garbage.

**Storage**

Store below 25°C  
(Air Conditioning).

**Presentation**

10 mL or 20 mL multidose vials.

Distributed by

**Australia**

Boehringer Ingelheim Pty Limited  
Animal Health Division  
Level 1  
78 Waterloo Road  
NORTH RYDE NSW 2113

APVMA No. 55529/1205

**New Zealand**

Boehringer Ingelheim (NZ) Limited  
Animal Health Division  
Level 1, Unit 9  
42 Ormiston Road  
East Tamaki Auckland

**Restricted Veterinary Medicine. No. A7550**

See [www.nzfsa.govt.nz/acvm](http://www.nzfsa.govt.nz/acvm)  
for registration condition